US2016096889A1PendingUtilityA1

B7-h1, a novel immunoregulatory molecule

63
Assignee: MAYO FOUNDATIONPriority: Nov 30, 1999Filed: Sep 3, 2015Published: Apr 7, 2016
Est. expiryNov 30, 2019(expired)· nominal 20-yr term from priority
Inventors:Lieping Chen
C07K 2317/526G01N 2333/70532C07K 16/00C07K 2317/76G01N 33/502A61K 38/00C07K 2317/24C07K 16/2827C07K 2317/524A61K 2035/124C07K 14/47C07K 14/70532C07K 2319/74A61K 39/39G01N 33/505
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 48 . (canceled) 
     
     
         49 . A method for recovering an antibody from hydridoma supernatant, comprising culturing an antibody-producing hybridoma in vitro in suitable medium to produce supernatant and recovering antibodies produced by said antibody-producing hybridoma from said supernatant, thereby obtaining said antibody, wherein said antibody is an anti-B7-H1 antibody. 
     
     
         50 . The method of  claim 49 , wherein said anti-B7-H1 antibody is an anti-hB7-H1 antibody. 
     
     
         51 . The method of  claim 49 , wherein said anti-B7-H1 antibody binds specifically to a B7-H1 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1. 
     
     
         52 . The method of  claim 49 , wherein said anti-B7-H1 antibody is a chimeric monoclonal antibody. 
     
     
         53 . The method of  claim 49 , wherein said anti-B7-H1 antibody is a humanized monoclonal antibody.

Join the waitlist — get patent alerts

Track US2016096889A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.